[go: up one dir, main page]

JO3264B1 - مركبات ازيتيدينيل أوكسي فينيل بيروليدين - Google Patents

مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Info

Publication number
JO3264B1
JO3264B1 JOP/2014/0068A JOP20140068A JO3264B1 JO 3264 B1 JO3264 B1 JO 3264B1 JO P20140068 A JOP20140068 A JO P20140068A JO 3264 B1 JO3264 B1 JO 3264B1
Authority
JO
Jordan
Prior art keywords
compounds
azitidine
phenylpyrrolidine
oxy
formula
Prior art date
Application number
JOP/2014/0068A
Other languages
English (en)
Inventor
O Odingo Joshua
Huang Danwen
G Deng Gary
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3264B1 publication Critical patent/JO3264B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات آزيتيدينيل أوكسي فينيل بيروليدين، وبخاصة مركبات لها الصيغة I حيث R هي الهيدروجين أو ميثيل، وتركيبات صيدلية منها. كما يقدم الاختراع طرق استخدام مركب له الصيغة I لعلاج المثانة مفرطة النشاط.
JOP/2014/0068A 2013-03-13 2014-03-04 مركبات ازيتيدينيل أوكسي فينيل بيروليدين JO3264B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
JO3264B1 true JO3264B1 (ar) 2018-09-16

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0068A JO3264B1 (ar) 2013-03-13 2014-03-04 مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Country Status (39)

Country Link
US (3) US9034864B2 (ar)
EP (2) EP3168216A1 (ar)
JP (2) JP6017708B2 (ar)
KR (2) KR101702797B1 (ar)
CN (2) CN105051034B (ar)
AP (1) AP3850A (ar)
AR (1) AR095015A1 (ar)
AU (1) AU2014241444B2 (ar)
BR (1) BR112015020222B1 (ar)
CA (1) CA2899806C (ar)
CL (1) CL2015002113A1 (ar)
CR (1) CR20150417A (ar)
CY (1) CY1120142T1 (ar)
DK (1) DK2970222T3 (ar)
DO (1) DOP2015000176A (ar)
EA (1) EA026631B1 (ar)
ES (1) ES2616470T3 (ar)
HR (1) HRP20170080T1 (ar)
HU (1) HUE032235T2 (ar)
IL (1) IL240904B (ar)
JO (1) JO3264B1 (ar)
LT (1) LT2970222T (ar)
MA (1) MA38410B1 (ar)
ME (1) ME02592B (ar)
MX (1) MX373636B (ar)
MY (1) MY180006A (ar)
NZ (1) NZ710481A (ar)
PE (1) PE20151669A1 (ar)
PH (1) PH12015502032A1 (ar)
PL (1) PL2970222T3 (ar)
PT (1) PT2970222T (ar)
RS (1) RS55594B1 (ar)
SG (2) SG10201609717YA (ar)
SI (1) SI2970222T1 (ar)
TN (1) TN2015000384A1 (ar)
TW (1) TWI617553B (ar)
UA (1) UA115583C2 (ar)
WO (1) WO2014159012A1 (ar)
ZA (1) ZA201505417B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CA3123995C (en) 2018-12-18 2023-05-23 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN112409333B (zh) * 2019-08-23 2024-06-14 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CZ20031903A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
CA2623657A1 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Also Published As

Publication number Publication date
US9034864B2 (en) 2015-05-19
DK2970222T3 (en) 2017-02-27
US9266859B2 (en) 2016-02-23
ZA201505417B (en) 2022-09-28
US20140275002A1 (en) 2014-09-18
PL2970222T3 (pl) 2017-06-30
CN105051034B (zh) 2019-05-21
TWI617553B (zh) 2018-03-11
CR20150417A (es) 2015-09-16
US20150133423A1 (en) 2015-05-14
CA2899806C (en) 2017-07-18
SG11201507501YA (en) 2015-10-29
MA38410B1 (fr) 2016-09-30
AR095015A1 (es) 2015-09-16
EA026631B1 (ru) 2017-04-28
IL240904B (en) 2019-02-28
ES2616470T3 (es) 2017-06-13
MA38410A1 (fr) 2016-02-29
BR112015020222A2 (pt) 2017-07-18
US20160122322A1 (en) 2016-05-05
JP2016510759A (ja) 2016-04-11
MX373636B (es) 2020-04-16
LT2970222T (lt) 2017-03-27
HK1212695A1 (en) 2016-06-17
KR101745304B1 (ko) 2017-06-08
AU2014241444A1 (en) 2015-08-06
EA201591498A1 (ru) 2015-12-30
CL2015002113A1 (es) 2016-01-15
TW201522327A (zh) 2015-06-16
MY180006A (en) 2020-11-19
KR101702797B1 (ko) 2017-02-06
IL240904A0 (en) 2015-10-29
KR20170013411A (ko) 2017-02-06
CN105051034A (zh) 2015-11-11
JP6017708B2 (ja) 2016-11-02
US9604967B2 (en) 2017-03-28
AP2015008699A0 (en) 2015-09-30
PT2970222T (pt) 2017-02-08
WO2014159012A1 (en) 2014-10-02
KR20150119077A (ko) 2015-10-23
CN109336865A (zh) 2019-02-15
JP6204557B2 (ja) 2017-09-27
HUE032235T2 (en) 2017-09-28
BR112015020222A8 (pt) 2018-01-23
AU2014241444B2 (en) 2016-04-07
NZ710481A (en) 2020-08-28
UA115583C2 (uk) 2017-11-27
BR112015020222B1 (pt) 2020-07-14
EP2970222B1 (en) 2016-12-21
WO2014159012A9 (en) 2014-12-18
TN2015000384A1 (en) 2017-01-03
SI2970222T1 (sl) 2017-02-28
CA2899806A1 (en) 2014-10-02
AP3850A (en) 2016-09-30
RS55594B1 (sr) 2017-06-30
JP2016216517A (ja) 2016-12-22
DOP2015000176A (es) 2015-11-15
HRP20170080T1 (hr) 2017-03-10
ME02592B (me) 2017-06-20
CY1120142T1 (el) 2018-12-12
SG10201609717YA (en) 2017-01-27
EP2970222A1 (en) 2016-01-20
EP3168216A1 (en) 2017-05-17
MX2015012579A (es) 2016-01-20
PH12015502032A1 (en) 2016-01-18
PE20151669A1 (es) 2015-11-12

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
UA110338C2 (xx) Хімічні сполуки
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
JO3773B1 (ar) معدلات p2x7
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201690894A1 (ru) Феноксиэтилы
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201500931A1 (ru) Производные пиридин-4-ила
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201690593A1 (ru) Новые соединения мочевины
CU20150043A7 (es) Inhibidores de la tirosina-quinasa de bruton